Background: Gender may affect growth hormone (GH) treatment outcome. This study assessed gender-related differences in change from baseline height standard deviation scores (ΔHSDS) after 2 years’ GH treatment. Methods: Data from two observational databases were analyzed – the NordiNet® International Outcome Study (NordiNet® IOS) and the American Norditropin Studies: Web Enabled Research Program (ANSWER Program®). Of all the evaluated patients (n = 5,880; age 0 to <18 years), 4,471 were diagnosed with GH deficiency (GHD), 422 with multiple pituitary hormone deficiency, and 987 were born small for gestational age (SGA). Data were analyzed by indication, gender and pubertal status (total population/prepubertal). Results: In the total population, after correcting for dose, mean baseline age and HSDS, ΔHSDS was significantly greater in boys than in girls born SGA (p = 0.0261). In the prepubertal cohort, ΔHSDS was significantly greater for boys versus girls with GHD (p = 0.0004) and SGA (p = 0.0019). No between-gender difference in ΔIGF-I SDS was found. Conclusions: A significant gender difference was found in the 2-year response to GH treatment in the total population of SGA children as well as in the prepubertal cohorts of SGA and GHD children.

Keywords:
Growth, Growth hormone treatment, Gender differences
1.
Ranke MB, Lindberg A, Chatelain P, et al: Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. J Clin Endocrinol Metab 1999;84:1174–1183.
2.
Mauras N, Rogol AD, Haymond MW, Veldhuis JD: Sex steroids, growth hormone, insulin-like growth factor-1: neuroendocrine and metabolic regulation in puberty. Horm Res 1996;45:74–80.
3.
Clark PA, Rogol AD: Growth hormones and sex steroid interactions at puberty. Endocrinol Metab Clin North Am 1996;25:665–681.
4.
van den Berg G, Veldhuis JD, Frölich M, Roelfsema F: An amplitude-specific divergence in the pulsatile mode of growth hormone (GH) secretion underlies the gender difference in mean GH concentrations in men and premenopausal women. J Clin Endocrinol Metab 1996;81:2460–2467.
5.
Rogol AD: Sex steroids, growth hormone, leptin and the pubertal growth spurt. Endocr Dev 2010;17:77–85.
6.
Maiorana A, Cianfarani S: Impact of growth hormone therapy on adult height of children born small for gestational age. Pediatrics 2009;124:e519–e531.
7.
Kuczmarski RJ, Ogden CL, Guo SS, et al: 2000 CDC growth charts for the United States: methods and development. Vital Health Stat 11 2002;246:1–190.
8.
Brabant G, von zur Mühlen A, Wüster C, et al: Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003;60:53–60.
9.
Cohen P, Bright GM, Rogol AD, et al: Effects of dose and gender on the growth and growth factor response to GH in GH-deficient children: implications for efficacy and safety. J Clin Endocrinol Metab 2002;87:90–98.
10.
Rose SR, Shulman DI, Larsson P, et al: Gender does not influence prepubertal growth velocity during standard growth hormone therapy – analysis of United States KIGS data. J Pediatr Endocrinol Metab 2005;18:1045–1051.
11.
Löfqvist C, Andersson E, Gelander L, et al: Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty. J Clin Endocrinol Metab 2001;86:5870–5876.
12.
Guercio G, Rivarola MA, Chaler E, Maceiras M, Belgorosky A: Relationship between the growth hormone/insulin-like growth factor-I axis, insulin sensitivity, and adrenal androgens in normal prepubertal and pubertal girls. J Clin Endocrinol Metab 2003;88:1389–1393.
13.
Demerath EW, Towne B, Wisemandle W, et al: Serum leptin concentration, body composition, and gonadal hormones during puberty. Int J Obes Relat Metab Disord 1999;23:678–685.
14.
Rose SR, Municchi G, Barnes KM, et al: Spontaneous growth hormone secretion increases during puberty in normal girls and boys. J Clin Endocrinol Metab 1991;73:428–435.
15.
Casanueva FF, Dieguez C: Interaction between body composition, leptin and growth hormone status. Baillieres Clin Endocrinol Metab 1998;12:297–314.
16.
Ranke M: KIGS: 20 years. Horm Res 2007;68(suppl 5):40.
17.
Saenger P: Growth hormone in growth hormone deficiency. BMJ 2002;325:58–59.
18.
Lee PA, Chernausek SD, Hokken-Koelega AC, et al: International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24–October 1, 2001. Pediatrics 2003;111:1253–1261.
19.
Ross J, Lee PA, Gut R, Germak J: Factors influencing the one- and two-year growth response in children treated with growth hormone: analysis from an observational study. Int J Pediatr Endocrinol 2010;2010:494656.
20.
Ross J, Savendahl L, Gruters A, et al: Gender differences in growth hormone (GH) responsiveness in growth hormone deficient (GHD) children and short children born small for gestational age (SGA). Hormone Res 2009;72(suppl 3):372.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.